Cost-effectiveness model was developed to compare costs and other factors of azacitidine/venetoclax combination with azacitidine alone in patients with AML.
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
Open-label, prospective study investigated the effects of preemptive administration of tocilizumab in pediatric patients with B-ALL undergoing CAR-T therapy.
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.